104 related articles for article (PubMed ID: 12019088)
61. Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency.
Thackray AM; Field HJ
J Infect Dis; 1996 Feb; 173(2):291-9. PubMed ID: 8568288
[TBL] [Abstract][Full Text] [Related]
62. Species differences in the disposition of acyclovir.
de Miranda P; Krasny HC; Page DA; Elion GB
Am J Med; 1982 Jul; 73(1A):31-5. PubMed ID: 7102710
[TBL] [Abstract][Full Text] [Related]
63. A quantitative study of the effects of several nucleoside analogues on established herpes encephalitis in mice.
Field HJ; Anderson JR; Efstathiou S
J Gen Virol; 1984 Apr; 65 ( Pt 4)():707-19. PubMed ID: 6323620
[TBL] [Abstract][Full Text] [Related]
64. Zosteriform spread of herpes simplex virus as a model of recrudescence and its use to investigate the role of immune cells in prevention of recurrent disease.
Simmons A; Nash AA
J Virol; 1984 Dec; 52(3):816-21. PubMed ID: 6092713
[TBL] [Abstract][Full Text] [Related]
65. The effects of acyclovir on antibody response to herpes simplex virus in primary genital herpetic infections.
Bernstein DI; Lovett MA; Bryson YJ
J Infect Dis; 1984 Jul; 150(1):7-13. PubMed ID: 6086772
[TBL] [Abstract][Full Text] [Related]
66. A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo.
Luby JP; Gnann JW; Alexander WJ; Hatcher VA; Friedman-Kien AE; Klein RJ; Keyserling H; Nahmias A; Mills J; Schachter J
J Infect Dis; 1984 Jul; 150(1):1-6. PubMed ID: 6086765
[TBL] [Abstract][Full Text] [Related]
67. Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters.
Rotman B; Papermaster BW
Proc Natl Acad Sci U S A; 1966 Jan; 55(1):134-41. PubMed ID: 5220862
[No Abstract] [Full Text] [Related]
68. Treatment of herpes labialis with acyclovir. Review of three clinical trials.
Raborn GW; McGaw WT; Grace M; Percy J
Am J Med; 1988 Aug; 85(2A):39-42. PubMed ID: 3044091
[TBL] [Abstract][Full Text] [Related]
69. Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans.
Efstathiou S; Minson AC; Field HJ; Anderson JR; Wildy P
J Virol; 1986 Feb; 57(2):446-55. PubMed ID: 3003377
[TBL] [Abstract][Full Text] [Related]
70. Comparison of the in vitro and in vivo antiherpes virus activities of the acyclic nucleosides, acyclovir (Zovirax) and 9-[(2-hydroxy-1-hydroxymethylethoxy)methyl]guanine (BWB759U).
Collins P; Oliver NM
Antiviral Res; 1985 Jun; 5(3):145-56. PubMed ID: 2992369
[TBL] [Abstract][Full Text] [Related]
71. Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1.
Meignier B; Longnecker R; Mavromara-Nazos P; Sears AE; Roizman B
Virology; 1988 Jan; 162(1):251-4. PubMed ID: 2827384
[TBL] [Abstract][Full Text] [Related]
72. Comparative efficacy of three antiviral drugs in mice herpetic keratitis.
Inoue Y; Ohashi Y; Shimomura Y; Manabe R; Yamada M; Ueda S; Kato S
Jpn J Ophthalmol; 1989; 33(1):125-31. PubMed ID: 2543857
[TBL] [Abstract][Full Text] [Related]
73. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome.
Erlich KS; Mills J; Chatis P; Mertz GJ; Busch DF; Follansbee SE; Grant RM; Crumpacker CS
N Engl J Med; 1989 Feb; 320(5):293-6. PubMed ID: 2536136
[No Abstract] [Full Text] [Related]
74. A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.
Whitley R; Arvin A; Prober C; Burchett S; Corey L; Powell D; Plotkin S; Starr S; Alford C; Connor J
N Engl J Med; 1991 Feb; 324(7):444-9. PubMed ID: 1988829
[TBL] [Abstract][Full Text] [Related]
75. Intranasal challenge of mice with herpes simplex virus: an experimental model for evaluation of the efficacy of antiviral drugs.
De Clercq E; Luczak M
J Infect Dis; 1976 Jun; 133 Suppl():A226-36. PubMed ID: 180205
[TBL] [Abstract][Full Text] [Related]
76. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293.
Betz UA; Fischer R; Kleymann G; Hendrix M; Rübsamen-Waigmann H
Antimicrob Agents Chemother; 2002 Jun; 46(6):1766-72. PubMed ID: 12019088
[TBL] [Abstract][Full Text] [Related]
77. Helicase primase: targeting the Achilles heel of herpes simplex viruses.
Kleymann G
Antivir Chem Chemother; 2004 May; 15(3):135-40. PubMed ID: 15266895
[TBL] [Abstract][Full Text] [Related]
78. Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections.
Biswas S; Sukla S; Field HJ
Future Med Chem; 2014 Jan; 6(1):45-55. PubMed ID: 24358947
[TBL] [Abstract][Full Text] [Related]
79. Helicase-primase as a target of new therapies for herpes simplex virus infections.
James SH; Larson KB; Acosta EP; Prichard MN
Clin Pharmacol Ther; 2015 Jan; 97(1):66-78. PubMed ID: 25670384
[TBL] [Abstract][Full Text] [Related]
80. HSV antivirals - current and future treatment options.
Birkmann A; Zimmermann H
Curr Opin Virol; 2016 Jun; 18():9-13. PubMed ID: 26897058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
